文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

心源性休克的晚期经皮机械循环支持装置

Advanced Percutaneous Mechanical Circulatory Support Devices for Cardiogenic Shock.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论心源性休克时经皮机械循环支持装置使用增加,但与主动脉内球囊反搏相比,Impella和TandemHeart改善血流动力学却不降低死亡率,且并发症率高。

本文综述了心源性休克的临时经皮机械循环支持装置,检索了MEDLINE中关于心源性休克、经皮机械循环支持、体外膜氧合、Impella和TandemHeart的文献。与主动脉内球囊反搏相比,Impella提供更大的血流动力学支持但无死亡率降低;TandemHeart改善血流动力学变量但不改善生存;静脉-动脉体外膜氧合提供双心室循环支持和氧合但有显著血管并发症。比较研究因样本量小对死亡率把握度不足,体外膜氧合的对比研究尚未完成。尽管缺乏随机对照数据,经皮机械循环支持的使用大幅增加。

要点

  • 与主动脉内球囊反搏相比,Impella提供更大的血流动力学支持,但无死亡率降低。
  • TandemHeart改善血流动力学变量,但不改善生存。
  • 静脉-动脉体外膜氧合提供双心室循环支持和氧合,但有显著血管并发症。
  • 比较研究因样本量小对死亡率把握度不足;体外膜氧合的对比研究尚未完成。
  • 尽管缺乏随机对照数据,经皮机械循环支持的使用已大幅增加。

适用人群与场景

  • 对血管加压药或主动脉内球囊反搏反搏治疗无效的心源性休克患者。

研究设计与关键结果

  • 综述纳入随机对照试验数据和观察性研究,描述经皮机械循环支持在心源性休克中的经验。
  • 与主动脉内球囊反搏相比,Impella提供更大的血流动力学支持但无死亡率降低。
  • TandemHeart改善血流动力学变量但不改善生存。
  • 比较研究因样本量小对死亡率把握度不足。
  • 静脉-动脉体外膜氧合提供双心室循环支持和氧合,但有显著血管并发症。
  • 体外膜氧合的对比研究尚未完成。
  • 尽管缺乏随机对照数据,经皮机械循环支持的使用已大幅增加。
  • 正在进行的若干前瞻性研究样本量更大,可能提供答案。

证据类型、等级与局限

  • 证据类型:综述,汇总随机对照试验数据与观察性研究。
  • 局限:比较研究因样本量小对死亡率把握度不足;体外膜氧合的对比研究尚未完成。

对床旁实践的改变

  • 作者认为,尽管证据缺乏且并发症率高,经皮机械循环支持的改进和经验可能带来更好结局的前景。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To review temporary percutaneous mechanical circulatory support devices for the treatment of cardiogenic shock, including current evidence, contraindications, complications, and future directions.

DATA SOURCES: A MEDLINE search was conducted with MeSH terms: cardiogenic shock, percutaneous mechanical circulatory support, extracorporeal membrane oxygenation, Impella, and TandemHeart.

STUDY SELECTION: Selected publications included randomized controlled trial data and observational studies describing experience with percutaneous mechanical circulatory support in cardiogenic shock.

DATA EXTRACTION: Studies were chosen based on strength of association with and relevance to cardiogenic shock.

DATA SYNTHESIS: Until recently, there were few options if cardiogenic shock was refractory to vasopressors or intra-aortic balloon pump counterpulsation. Now, several percutaneous mechanical circulatory support devices, including Impella (Abiomed, Danvers, MA), TandemHeart (CardiacAssist, Pittsburgh, PA), and extracorporeal membrane oxygenation, are more accessible. Compared with intra-aortic balloon pump, Impella provides greater hemodynamic support but no reduction in mortality. Similarly, TandemHeart improves hemodynamic variables but not survival. Comparative studies have been underpowered for mortality because of small sample size. Veno-arterial extracorporeal membrane oxygenation offers the advantage of biventricular circulatory support and oxygenation, but there are significant vascular complications. Comparative studies with extracorporeal membrane oxygenation have not been completed. Despite lack of randomized controlled data, there has been a substantial increase in use of percutaneous mechanical circulatory support. Several ongoing prospective studies with larger sample sizes may provide answers, and newer devices may become smaller, easier to insert, and more effective.

CONCLUSIONS: Mortality from cardiogenic shock remains unacceptably high despite early coronary revascularization or other therapies. Although evidence is lacking and complications rates are high, improvements and experience with percutaneous mechanical circulatory support may offer the prospect of better outcomes.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Miller PE, Solomon MA, McAreavey D, et al. Advanced Percutaneous Mechanical Circulatory Support Devices for Cardiogenic Shock. Crit Care Med. 2017. PMID: 28857849. doi:10.1097/CCM.0000000000002676

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。